Figure 1From: Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial [ISRCTN85429598] Bone markers in women randomized to simvastatin 40 mg daily. Plasma concentrations of bone ALP, CTX-I and NTX-I at baseline, and after 6 and 12 weeks of simvastatin 40 mg qhs are shown for each woman assigned to that treatment group.Back to article page